

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Canceled)

2. (Currently amended) The ~~composition~~ method according to ~~claim 1~~ claim 18, wherein the LK68 encoding molecule comprises a nucleotide sequence represented by SEQ ID NO:1.

3-6. (Canceled)

7. (Currently amended) The ~~composition~~ method according to ~~claim 1~~ claim 18, wherein the gene carrier is selected from pSecTag-LK68, pLXSN-LK68, rAAV-LK68, pAAV-LK68, pSecTag-LK8, pLXSN-LK8, rAAV-LK8 and pAAV-LK8.

8. (Currently amended) The ~~composition~~ method according to ~~claim 1~~ claim 18, wherein the LK8 encoding molecule comprises a nucleotide sequence represented by SEQ ID NO:2.

9-12. (Canceled)

13. (Currently amended) The ~~composition~~ method according to ~~claim 3~~ claim 18, wherein the plasmid is present in an amount of 0.05 ~ 500 mg.

14. (Currently amended) The ~~composition~~ method according to ~~claim 3~~ claim 18, wherein the adeno-associated virus or adenovirus is present in an amount of 10^3 - 10^{12} IU.

15. (Canceled)

16. (Previously presented) The ~~composition method~~ according to ~~claim 1~~ claim 18, wherein the solid tumor is selected from colon carcinoma, liver cancer, lung cancer, breast cancer, brain tumor, prostatic carcinoma, skin cancer, stomach cancer, pancreas cancer, lymphoma, kidney cancer, ovarian cancer and metastatic tumor.

17. (Previously presented) The ~~composition method~~ according to claim 16, wherein the solid tumor is selected from colon carcinoma, liver cancer, lymphoma and metastatic tumor.

18. (Currently amended) A method for ~~preventing or~~ treating solid tumor in a subject, comprising ~~administering parenterally~~ directly injecting or intramuscularly injecting to the subject a ~~gene carrier, or ex vivo cells,~~ plasmid, adeno-associated virus or adenovirus harboring a nucleic acid molecule encoding a ~~recombinant~~ human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8), ~~wherein said gene carrier or ex vivo cells express said molecule to prevent or treat said solid tumor in the subject.~~

19. (Previously presented) The method according to claim 18, wherein the prevention or the treatment of a solid tumor in the subject is accomplished by inhibition of growth and metastasis of the solid tumor.

20. (Currently amended) The method according to claim 18, wherein the administration of a ~~gene carrier~~ plasmid, adeno-associated virus or adenovirus harboring human apolipoprotein(a) kringle KIV9-KIV10-K V (LK68) or K V (LK8) encoding molecule is accomplished by a method selected from chemical method, physical method, conjugation using liposome, a method using receptor and virus.

21-23. (Canceled)

24. (Currently amended) The ~~composition~~ method according to claim 5, wherein the viral gene carrier is adenovirus.

25. (Currently amended) The ~~composition~~ method according to claim 5, wherein the viral gene carrier is adeno-associated virus.